Trial Profile
Atomoxetine for Attention-deficit hyperActivity disorder Symptoms in children with pervasive developmental disorders: a pilot study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Mar 2021
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Asperger syndrome; Attention-deficit hyperactivity disorder; Autistic disorder; Pervasive child development disorders
- Focus Therapeutic Use
- Acronyms AAAS
- 05 Mar 2007 New trial record.